Roche perceives Carmot's assets, especially CT-388, as havin...
Roche perceives Carmot's assets, especially CT-388, as having leading potential for weight loss treatment. Roche CEO believes combining Carmot's portfolio with Roche's resources can elevate patient care globally.
Roche Ventures Into Weight-loss Drug Market With $2.7B Buyout of Carmot
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment